0000000000991462

AUTHOR

Andrea Micheli

showing 2 related works from this author

Age and case mix-standardised survival for all cancer patients in Europe 1999-2007: Results of EUROCARE-5, a population-based study

2015

Background: Overall survival after cancer is frequently used when assessing a health care service’s performance as a whole. It is mainly used by the public, politicians and the media, and is often dismissed by clinicians because of the heterogeneous mix of different cancers, risk factors and treatment modalities. Here we give survival details for all cancers combined in Europe, correlating it with economic variables to suggest reasons for differences. Methods: We computed age and cancer site case- mix standardised relative survival for all cancers combined (ACRS) for 29 countries participating in the EUROCARE-5 project with data on more than 7.5 million cancer cases from 87 population-based…

Cancer ResearchPopulationPopulation-based cancer registrieAll cancerGross domestic productCase-mix by cancer siteCase mix indexHealth careMedicineeducationMETIS-311842education.field_of_studyRelative survivalbusiness.industryCancerCancer survivalPopulation-based cancer registriesmedicine.diseaseCancer survivalEastern europeanOncologyAll cancer ; Cancer survival ; Case-mix by cancer site ; EUROCARE ; Population-based cancer registriesbusinessEUROCAREIR-97293Demography
researchProduct

European disparities in malignant digestive endocrine tumours survival.

2009

The aim of this study was to report on malignant digestive endocrine tumours (MDET) prognosis in several European countries. We analysed survival data from 19 cancer registries in 12 European countries on 3,715 MDET diagnosed between 1985 and 1994. The overall 5-year survival rate was 47.5%. It was 58.1% for differentiated MDET and 8.1% for small-cell MDET (p < 0.001), 55.9% for patients under 65 and 37.0% for older patients. Survival rates for small intestinal and colorectal were higher than for the other sites. The 5-year relative survival rates were 60.3% in Northern Europe, 53.6% in Western Continental Europe, 42.5% in the UK, 37.6% in Eastern Europe (p < 0.001). Among well-differentiat…

MaleCancer Researchmedicine.medical_specialtyPathologyGlucagonomaDigestive System NeoplasmsGastroenterologydigestive endocrine tumours survivalInternal medicineEndocrine Gland NeoplasmsmedicineHumansCarcinoid tumourRegistriesSurvival rateAgedNeoplasm StagingGastrinomaRelative survivalbusiness.industryAbsolute risk reductionCancerMiddle Agedmedicine.diseasePrognosisCancer registryEuropeSurvival RateOncologyFemalebusinessInternational journal of cancer
researchProduct